Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

ImmunityBio (IBRX) Shares Outstanding (Diluted Average) (2019 - 2025)

Historic Shares Outstanding (Diluted Average) for ImmunityBio (IBRX) over the last 7 years, with Q3 2025 value amounting to $946.6 million.

  • ImmunityBio's Shares Outstanding (Diluted Average) rose 3562.38% to $946.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $946.6 million, marking a year-over-year increase of 3562.38%. This contributed to the annual value of $700.4 million for FY2024, which is 3771.01% up from last year.
  • According to the latest figures from Q3 2025, ImmunityBio's Shares Outstanding (Diluted Average) is $946.6 million, which was up 3562.38% from $888.2 million recorded in Q2 2025.
  • In the past 5 years, ImmunityBio's Shares Outstanding (Diluted Average) registered a high of $946.6 million during Q3 2025, and its lowest value of $382.7 million during Q1 2021.
  • In the last 5 years, ImmunityBio's Shares Outstanding (Diluted Average) had a median value of $437.5 million in 2023 and averaged $550.7 million.
  • As far as peak fluctuations go, ImmunityBio's Shares Outstanding (Diluted Average) soared by 209.42% in 2022, and later skyrocketed by 5706.35% in 2024.
  • Over the past 5 years, ImmunityBio's Shares Outstanding (Diluted Average) (Quarter) stood at $389.2 million in 2021, then grew by 2.74% to $399.9 million in 2022, then rose by 27.19% to $508.6 million in 2023, then soared by 37.71% to $700.4 million in 2024, then skyrocketed by 35.14% to $946.6 million in 2025.
  • Its Shares Outstanding (Diluted Average) was $946.6 million in Q3 2025, compared to $888.2 million in Q2 2025 and $853.2 million in Q1 2025.